We have identified by MEDLINE search the cases of gammaglobinopathy and plasma cell malignancy in HIV-positive patients reported in the English language literature. The average age at presentation among HIV-positive patients with plasma cell disorders is 33 years, far younger than the average age of presentation in the general population. Some of these patients present with transient paraproteinemias, while others have persistent paraproteins, which may or may not be associated with true plasma cell malignancies. In most cases in which it has been examined, the paraprotein contains high-titer anti-HIV activity. The presence of high-titer anti-HIV activity in the paraproteins of AIDS patients suggests that an antigen-driven process in response to HIV infection may contribute to the early development of plasma cell disorders in these patients. Recent work in plasma cell tumorigenesis has indicated that transformation at a single point in the B lymphocyte lineage can give rise to either lymphoma or myeloma, dependent upon environmental factors such as T cell function, which may be required for directing transformed lymphocytes from lymphoma and towards plasma cell differentiation. This may explain why B lineage oncogenesis in AIDS patients favors the development of lymphoma over that of myeloma.
Introduction
An increased globulin fraction is a common incidental laboratory finding in patients infected with HIV; in these cases, serum protein electrophoresis usually reveals a polyclonal gammaglobinopathy. [1] [2] [3] [4] Although HIV-infected individuals have deficiencies in CD4-positive T helper cells, and thus might be expected to have problems with B cell activation and immunoglobulin secretion, experimental studies of B lymphocytes in HIV infection have revealed polyclonal B cell activation. 3, 5 B cells exposed to HIV in vitro may proliferate 6 or become activated and begin secreting immunoglobulin. 4, 7, 8 HIV-infected T cells can induce contact-dependent but antigen-independent polyclonal activation of B cells. 9 Bone marrow biopsy of HIV-infected patients commonly reveals a plasmacytosis, even in the absence of any plasma cell disorder. 1, 10 A distinct but related phenomenon less frequently observed in AIDS patients is mono-or oligoclonal gammaglobinopathy. Briault and co-workers 11 observed mono-or oligoclonal antibodies in the sera of 26% of 62 HIV-positive patients at various stages of infection. As in non-HIV-infected individuals, a monoclonal gammopathy may be associated with no other disorders and thus be characterized as a monoclonal gammopathy of undetermined significance (MGUS), or may be associated with plasma cell disorders including multiple myeloma, plasmacytoma, Waldenströ m's macroglobinemia or primary amyloidosis. 
Monoclonal gammopathy and the progression to myeloma
The natural history of MGUS in the general population has been extensively studied by Kyle. 12 MGUS is found in approximately 1% of those older than 50 years and 3% of those over 70 years. Kyle has followed a group of 241 patients with MGUS for 20 to 35 years, [12] [13] [14] [15] and categorized their clinical course: 19% had no significant change, 10% had an increase in monoclonal gammopathy to over 3.0 g/dl without an associated disorder, 47% died of unrelated disease and 24% went on to develop a plasma cell disorder. Of these patients, 66% developed multiple myeloma, 12% macroglobinemia, 14% amyloidosis and 8% other lymphoproliferative disease after a median follow-up of 10 years from the recognition of the gammopathy. These data might indicate that there are two sets of patients with MGUS -those in whom it represents a benign condition, and those in whom it represents a precursor lesion to a plasma cell neoplasm. However, no clinical or laboratory markers have been shown to distinguish between these two proposed groups of patients. Alternatively, and more likely, MGUS may represent a stage in the development of a plasma cell neoplasm, with only a fraction of MGUS patients living long enough to develop clinically apparent malignancy. In this model, a monoclonal gammopathy, reflecting a clonal expansion of plasma cells, is the plasma cell equivalent to the solid tumor carcinoma in situ, representing a pre-malignant lesion at risk for further transformation and evolution into a full blown malignancy. Such models of epithelial tumor progression are well established. [16] [17] [18] Thus, multiple factors including genetic susceptibility and environmental exposure, determine if an individual will develop monoclonal gammopathy, and then if that premalignant lesion will develop into a plasma cell neoplasm.
Some of the factors responsible for the progression to myeloma have recently been identified, and include growth factor stimulation, oncogene activation, tumor suppressor gene inactivation, altered expression of cell adhesion molecules, and disrupted immunoregulation; paracrine and perhaps autocrine stimulation by interleukin-6 (IL-6) and activation of the c-myc oncogene have been strongly implicated. [19] [20] [21] [22] [23] [24] Comparison of myelomatous and normal plasma cells has revealed activation of various oncogenes, 19, 24 disruption of tumor suppressor genes, 19, 24 mutations in the IL-6 transducer protein gp130, 22 and altered expression of cell differentiation (CD) antigens. 25, 26 Further progression of multiple myeloma, characterized clinically by escape from the plateau phase, may be mediated by these factors as well as additional mechanisms such as enhanced nucleoside transport and multidrug resistance. 21 Recent investigations have begun to elucidate from where in the B cell lineage the malignant myeloma clones originate. 27 On the basis of immunoglobulin and other gene sequences, B lymphocytes clonally related to malignant plasma cells have been identified in the bone marrow [28] [29] [30] [31] and peripheral blood 28, 30, [32] [33] [34] [35] [36] [37] of myeloma patients. Myeloma cells, as well as these clonally related lymphocytes, express immunoglobulin genes that have undergone somatic hyper-Thus, transformation occurs after somatic hypermutation, and the lack of subsequent mutation indicates that the malignant, clonal lymphocyte-plasma cell population has escaped the antigen selection process. Lymphocyte populations clonally related to myeloma cells undergo class switching, 30, 31, 36, 41 indicating that transformation occurs prior to class switching and leaves intact either the switching mechanisms or a preprogrammed switch. The transformed population in myeloma thus appears to be restricted to the myelomatous plasma cells and clonally related, hypermutated, pre-switched B lymphocyte populations found in the bone marrow or periphery. These lymphocytes may comprise a non-malignant population related to the myeloma clone, or may be the true malignant cell population, driven by genetic and environmental cues to differentiate into plasma cells.
35 CD34-positive stem cells do not appear to contain cells related to the malignant clone. 29, 42 The differentiation stimuli needed to drive a transformed B cell to a plasma cell phenotype have also been studied. In nude mice, a retrovirus containing c-myc and c-raf gives rise to non-immunoglobulin secreting B cell lymphomas, whereas the same retrovirus gives rise to plasmacytomas in both normal mice and nude mice that have had T cell reconstitution. 43 The Abelson murine leukemia virus alone induces a pre-B cell lymphoma, but in combination with the constitutively expressed c-myc, it gives rise to plasmacytomas. 44 These data are consistent with a model in which transformation occurs in B lymphocytes that have undergone somatic hypermutation but are still capable of class switching, and certain stimuli, such as T cell regulation and oncogene expression, are critical in promoting differentiation of the transformed B cells into malignant plasma cells, not lymphoma cells.
The mechanism by which aberrant growth factor regulation and oncogene activation occur has not been elucidated. A theory of antigen-driven expansion and selection has been applied to B cell neoplasms and has received some experimental support. [45] [46] [47] [48] [49] Chronic antigenic stimulation, which might result from self-reactive lymphocytes, provides a selective stimulus for a clonal subgroup of B cells. The expansion of a clonal lymphocyte population increases the likelihood of sustaining mutations leading to neoplastic transformation. This model can account for the development of multiple myeloma: a B lymphocyte population chronically exposed to antigen will proliferate and, if the environmental and genetic circumstances are correct, one or more members of the proliferating B cell population might sustain a transforming mutation. In this way, a single or several clones escape from antigen-and stimulus-dependent proliferation. These B lymphocytes may still respond to environmental differentiation cues, giving rise to an expanded population of clonal immunoglobulinsecreting plasma cells (ie MGUS). Alternatively, the nature of the transforming events might affect the differentiation of the transformed cells. 44 In either case, the antigen-independent B cells would have an increased chance of sustaining a second transforming event that would render a clone malignant, resulting in plasmacytoma or multiple myeloma. The identification in some MGUS patients of circulating lymphocytes clonally related to the paraprotein-producing plasma cells, 36, 50 and the observation in some MGUS patients of ongoing somatic hypermutation in the clonally expanded cell population, 38 support this model.
Gammopathy and plasma cell tumors in AIDS
A number of cases of mono-and oligoclonal gammopathy, plasmacytoma, and multiple myeloma occurring in HIVinfected patients have been reported in the English literature; these are summarized in Tables 1 and 2 . The diagnosis of multiple myeloma can be difficult to make in an AIDS patient because these patients often have renal failure, anemia, thrombocytopenia and bone marrow plasmacytosis 1 simply as a consequence of HIV infection, opportunistic pathogens, and/or medications. Thus we have considered the presence of lytic bone lesions, hypercalcemia, or documented monoclonal plasma cell expansion necessary to classify a case as multiple myeloma.
HIV-positive patients with plasma cell disorders are distinguishable from non-infected patients both by the number of patients and by the age at presentation. While the overall incidence of monoclonal gammopathy in the general population is 0.15%, 75 the incidence of monoclonal or mono-and oligoclonal gammopathy in AIDS patients has been reported as 2.5% (monoclonal only), 58 72 Using isoelectric focusing, Sinclair and co-workers 76 reported an incidence of 61% for oligoclonal gammopathy. These studies have been of relatively small patient populations, perhaps accounting for the variability. However, these results do establish that the incidence of mono-and oligoclonal gammopathy in HIV-positive patients is increased over that observed in the general population. Similarly, the median age of HIV-negative patients with MGUS is 64 years, with only 4% younger than 40 years, and a 10 year period before the development of plasma cell neoplasm in the subpopulation that progresses; 12 Ishida and Dorfman 77 found fewer than 25 well-documented reports in the literature of multiple myeloma occurring before the age of 30 years. Two recent reports from Kyle's group have described patients with myeloma under the age of 40 (only 2% of myeloma patients) 78 and under the age of 30 (only 0.3% of myeloma patients). 79 In contrast to the general population, the mean patient age in the reported cases of MGUS, plasmacytoma and myeloma in AIDS patients is 33 years (34 years for MGUS, 32 years for documented neoplasms). Why the development and/or progression of plasma cell neoplasms is accelerated in AIDS patients has not been investigated, although the pathogenic mechanisms may be similar to those proposed for lymphoma development in AIDS patients. These mechanisms include genetic disturbances resulting in oncogene activation, HIVinduced immunosuppression allowing expansion of EpsteinBarr virus (EBV)-infected/immortalized B cells, and chronic antigenic stimulation causing B cell proliferation. 45 EBV and Kaposi sarcoma-associated herpes virus sequences and c-myc mutations have been identified in HIV-related lymphomas, 5, 80, 81 and an increased number of EBV-positive B cells are found in AIDS patients, perhaps due to a defect in T cell-mediated suppression of EBV-positive B cells. 4, 82 The broad activation of B lymphocytes in HIV infection is wellcharacterized. [3] [4] [5] [7] [8] [9] This B cell activation, with the expansion of EBV-infected B cell populations, may be the initial steps in B lineage tumorigenesis and may account for the high frequency of oligoclonal lymphoma observed in these patients. 5 Such a broad lymphocyte activation may predispose to the generation of lymphoma even in the absence of EBV infection.
Several additional factors may play a role. Elevated levels of IL-6, important in the etiology of multiple myeloma, are found in the sera of AIDS patients, 3 ,83-85 although this has not 88 while in vitro, IL-6 is produced by monocytes exposed to HIV 83 and B cells exposed to HIV and IL-4.
6 Elevated IL-6 levels would result in stimulation of plasma cells and certainly could contribute to the increased incidence of gammopathy in HIV infection. Another factor in AIDS patients is antigen-driven tumorigenesis. In HIV-negative patients, this model postulates chronic antigenic stimulation of self-reactive B lymphocyte populations. In AIDS patients, the antigenic stimulus is postulated to be not an auto-antigen, but rather the viral proteins of HIV. The induction in nude mice exposed to a transforming virus of plasmacytoma only in the presence of T cells 43 provides a possible explanation for the high frequency of lymphoma compared to myeloma in AIDS patients: the disrupted T cells in AIDS patients may be unable to provide the appropriate stimuli to drive the differentiation of tumorigenic lymphocytes into plasma cells. Thus, multiple mechanisms can account for the early development of MGUS, plasmacytoma, and multiple myeloma in HIV-infected individuals: direct activating effects of the virus on B cells, altered T cell regulation of B cells, infection with EBV, increased levels of IL-6, and chronic exposure to HIV antigens all may contribute to the increased incidence of B lineage neoplasms, while severely deranged T cell function might explain why the vast majority of these lymphocytic malignancies are lymphoma and not plasmacytoma or myeloma.
If plasma cell malignancy in AIDS patients is indeed driven by HIV antigens, then the antibodies secreted by these clonal or oligoclonal plasma cell populations should be, in most cases, specific for HIV antigens. Lefrère and colleagues 58 reported that half of one patient's anti-HIV activity could be accounted for by the monoclonal paraprotein. Papadopoulos and coworkers 74 demonstrated that oligoclonal paraproteins from an HIV-positive patient reacted strongly with HIV antigens, whereas gammaglobulin from an HIV-positive patient with polyclonal gammopathy reacted only weakly. Ng and co-workers 61, 63 purified paraproteins from the sera of HIVinfected patients. In five of seven cases, they found that the monoclonal paraproteins actually consisted of multiple comigrating IgG1 antibodies with specificities for different HIV antigens. In the other two cases, the paraproteins were monoclonal, non-HIV reactive IgG3 and IgA . Most recently, Konrad and co-workers 67 described a monoclonal IgG paraprotein that reacts specifically with the HIV p24 gag protein.
These results are supportive of a role for chronic antigenic stimulation by viral proteins in the etiology of MGUS and plasma cell malignancies in AIDS patients. An alternative explanation is that the paraproteinemia seen in AIDS patients is not MGUS at all, but rather part of the normal response to HIV infection. 63, 74 However, even if the B cell lineages generating mono-and oligoclonal paraproteins in HIV-infected patients have not undergone partial transformation, the cells in those lineages are, nevertheless, hyperstimulated and therefore at increased risk for transformation.
Lefrère and co-workers 58,68,89 have followed HIV-positive patients with mono-and oligoclonal gammopathies for up to 69 months. They noted that a number of these patients experienced transient gammopathies lasting for 1-2 years, whereas others had persistent gammopathy. 68, 89 The size of the monoclonal component correlated with longevity: persistent monoclonal gammopathies averaged 14.3 g/l, and transient monoclonal gammopathies averaged 4.2 g/l. 68 None of the patients were reported to develop B lineage malignancies over the follow-up periods (averages, 2 years 89 and 4 years 68 ); thus, the authors conclude that monoclonal gammopathy is not a prelymphomatous state. However, they did not provide clinical or laboratory data to indicate whether any of these patients might have developed a plasma cell neoplasm. Ng and colleagues 63 followed several patients for 2-4 years and others for shorter periods without progression; one of these patients presented with paraproteinemia and a lymphoma, and another lost his paraprotein after developing primary biliary lymphoma. 57, 63 Although these cases suggest that paraproteinemia in AIDS patients is not a precursor lesion for malignancy, this may be true only for low concentration, transient paraproteins as described by Lefrère. 68 The presence of such immunoglobulins may indeed reflect a temporary expansion of a clonal population in response to an antigenic challenge, be it from HIV or from an opportunistic infection. Alternatively, small, transient monoclonal gammopathies might simply reflect the fluctuating ability of the HIV-infected immune system to control a monoclonal expansion, even a truly premalignant one. Moreover, the follow-up time of these studies is much less than the median of 10 years between detection of paraproteinemia and onset of plasma cell neoplasm seen in the general population. The high concentration, persistent paraproteins reported by Lefrère 68 and others (paraprotein concentrations of 65, 52 64, 67 43 63 and 37 61 g/l have been described) are much more likely to represent pre-malignant states, similar to MGUS in the general population. Conclusive proof, however, must come from long-term follow-up of MGUS-positive AIDS patients who are carefully screened for signs of B lineage neoplasms, particularly plasma cell malignancies. A limiting factor is that many patients with AIDS succumb to infections or other processes before developing plasma cell malignancies.
Conclusions
In the context of recent advances in understanding the pathogenesis of MGUS and myeloma, we have reviewed the literature describing plasma cell disorders (paraproteinemia, plasmacytoma and multiple myeloma) in HIV-infected individuals. MGUS, a precursor lesion for multiple myeloma, may result from a partial transformation that leaves a clonal B cell population expanded but antigen-responsive; further transformation results in the malignant growth of a single clone. Myeloma is believed to develop from such transformed B cells that have undergone somatic hypermutation but are capable of isotype switching. Current models suggest that clonal, transformed lymphocytic precursors to myeloma cells are antigenindependent but, under the influence of T cells, c-myc overexpression, and other factors, are able to differentiate into plasma cells. In HIV infection, multiple factors contribute to the increased incidence of B cell neoplasms, including direct activating effects of the virus, activation and dysregulation of B cells, EBV and Kaposi sarcoma-associated herpes virus infections, increased levels of IL-6, and chronic antigen exposure. Paraproteins in AIDS patients have been identified as HIV-specific, supporting the idea that exposure to viral antigens drives B lymphocyte and plasma cell expansions. T cell dysfunction and depletion in AIDS patients may direct the differentiation of transformed lymphocytes to lymphoma rather than plasma cell malignancy, as T cells are crucial for the induction of plasmacytoma in a mouse model. 43 Although gammopathy, plasmacytoma and myeloma appear to occur far earlier in AIDS patients than in the general population, an increased risk of malignancy in AIDS patients with paraproteins has not been documented. Few patients have been followed long term, and screening for plasma cell neoplasms has not been undertaken. A study prospectively assessing the HIV specificity of paraproteins in AIDS patients, with long-term clinical follow-up and plasma cell malignancy screening, would address many of these issues, including the question of disrupted T cell function as a permissive condition for the development of lymphoma, but not myeloma.
